Shawn Patrick Griffin

Picture of Shawn Patrick Griffin
Health Sciences Assistant Clinical Professor, Department of Clinical Pharmacy Practice
School of Pharmacy & Pharmaceutical Sciences
Pharm.D., UNC Eshelman School of Pharmacy, 2014
B.S., Boston College, 2010, Biology
Phone: (949)824-8009
University of California, Irvine
286 Berk Hall
Mail Code: 4265
Irvine, CA 92697
Research Interests
Leukemia, stem cell transplant, cellular therapy, pharmacotherapy, dosing of medications in obesity, graft versus host disease, supportive care
Awards and Honors
2022, American College of Clinical Pharmacy, Hematology/Oncology PRN Emerging Member Award
Short Biography
Shawn Griffin is a Health Sciences Assistant Clinical Professor in the Department of Clinical Pharmacy Practice at the University of California, Irvine (UCI) School of Pharmacy & Pharmaceutical Sciences. He was hired as a founding faculty member within the new Doctor of Pharmacy Program and is currently developing both didactic and experiential courses for student pharmacists. Griffin also practices as a Board Certified Oncology Pharmacist within the Hematopoietic Stem Cell Transplantation and Cellular Therapy Program at the Chao Family Comprehensive Cancer Center where he has worked to create new pharmacist-provided clinical services. His research interests include investigating the role of pharmacists in clinical practice and optimizing the dosing of oncology-related medications in special populations.
Griffin SP, Signorelli JR, Lasko A, Andrick BJ, Doan D, Hough S, Riebandt G, Harnicar S. Oncology pharmacy practice in the United States: Results of a comprehensive, nationwide survey. Journal of Oncology Pharmacy Practice. 2023;Epub ahead of print. doi: 10.1177/10781552231174858.
Lee BJ, Kongtim P, Doh J, Griffin SP, Chan A, O'Brien S, Ciurea SO, Jeyakumar D. Impact of triple intrathecal prophylaxis in acute lymphoblastic leukemia adults receiving HyperCVAD: A COVID-19 practice change. European Journal of Haematology. 2023; Epub ahead of print. doi: 10.1111/ejh.13980.
Vittayawacharin P, E'Leimat G, Lee BJ, Griffin SP, Doh J, Nam H, Blodget E, Jeyakumar D, Kongtim P, Ciurea SO. Once-daily foscarnet is effective for human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Transplantation and Cellular Therapy. 2023;S2666-6367(4):1132-6. doi: 10.1016/j.jtct.2023.02.022.
Lee BJ, Griffin SP, Doh J, Kongtim P, Chan A, O’Brien S, Jeyakumar D, Ciurea SO. Timing of intrathecal chemotherapy and blinatumomab impacts neurotoxicity in acute lymphoblastic leukemia. American Journal of Hematology. Published online. doi: 10.1002/ajh.26880.
Lee BJ, Griffin SP, Doh J, Chan A, O’Brien S, Jeyakumar D, Ciurea SO, Becker PS, Kongtim P. CD19-directed immunotherapy use in KMT2A-rearranged acute leukemia: A case report and literature review of increased lymphoid to myeloid lineage switch. American Journal of Hematology. 2022;97(12):E439-43. doi: 10.1002/ajh.26713.
Benitez LL, Perissinotti AJ, Rausch CR, Klaus J, Clark SM, Filtz M, Ratermann K, Treptow C, Griffin SP, Olson M, Crain M, Kadia T, Pettit K, Burke PW, Bixby DL, Marini BL. Multicenter comparison of high-dose cytarabine based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. Leukemia & Lymphoma. 2021;Online ahead of print. doi: 10.1080/10428194.2021.1907378.
Christian S, Arain S, Patel P, Khan I, Calip GS, Agrawal V, Sweiss K, Griffin SP, Cahill K, Konig H, Esen A, Shergill A, Odenike O, Stock W, Quigley JG. A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. American Journal of Hematology. 2020;95(8):937-43. doi: 10.1002/ajh.25838.
Chen F, Wu X, Niculite C, Gilca M, Petrusca D, Rogozea A, Rice S, Guo B, Griffin SP, Calin GA, Boswell HS, Konig H. Classic and targeted anti-leukaemic agents interfere with the cholesterol biogenesis metagene in acute myeloid leukaemia: Therapeutic implications. Journal of Cellular and Molecular Medicine. 2020;24(13):7378-92. doi: 10.1111/jcmm.15339.
Agrawal A, Ranganath P, Ervin KD, Schmidt CA, Cox EA, Nelson RP, Schwartz JE, Abu Zaid M, Abonour R, Robertson MJ, Brinda BJ, Griffin SP, Thakrar TC, Farag SS. Effect of Sirolimus levels between days 11 and 20 after allogeneic stem cell transplantation on the risk of hepatic sinusoidal obstruction syndrome. Bone Marrow Transplantation. 2020;Online ahead of print. doi: 10.1038/s41409-020-0987-1.
Hickey EL, Clemons B, Griffin SP, Cox J, Sutphin S, Ramlal R, Benitez L. Multi-center Evaluation of Arsenic Trioxide Dosing in Obese Patients with Low-Intermediate Risk Acute Promyelocytic Leukemia. Leukemia & Lymphoma. 2019;60(14):3557-60. doi: 10.1080/10428194.2019.1639163.
Griffin SP, Wheeler SE, Wiggins LE, Murthy HS, Hsu JW, Richards AI. Pharmacokinetic and Clinical Outcomes When Ideal Body Weight is Used to Dose Busulfan in Obese Hematopoietic Stem Cell Transplant Recipients. Bone Marrow Transplantation. 2019;54(2):218-225. doi: 10.1038/s41409-018-0240-3.
Griffin SP, Nelson JE. Impact of a Clinical Solid Organ Transplant Pharmacist on Tacrolimus Nephrotoxicity, Therapeutic Drug Monitoring, and Institutional Revenue Generation in Adult Kidney Transplant Recipients. Progress in Transplantation. 2016; 26(4):314-321. doi: 10.1177/1526924816667950.
2023, Hematology/Oncology Pharmacy Association (HOPA) Early Career Research Award Primary investigator Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation Correlative PharmacoKinetic Study (ADAPT-PK). USD $49,999.89.
2022, UCI Genetic Epidemiology Research Institute, All of Us Data Funding Opportunity Co-investigator (Primary Investigator: Nana Entsuah) Psychological Distress and Medication Misuse during COVID-19 across Racial-ethnic Minority Identities (PICAR). USD $2,500.
2021, Hematology/Oncology Pharmacy Association (HOPA) Research Award Co-investigator (Primary Investigator: Alex Chan) Patient-Reported Outcomes (PRO)-driven pharmacy education In ethnic minOrity patients Receiving antIcancer TherapIES (PRIORITIES). USD $38,116.
Professional Societies
American Society for Transplantation and Cellular Therapy
Hematology/Oncology Pharmacy Association
American College of Clinical Pharmacy
California Society of Health-System Pharmacists
Other Experience
PGY2 Oncology Pharmacy Resident
University of Florida Health Shands Hospital 2015—2016
PGY1 Pharmacy Resident
University of Florida Health Shands Hospital 2014—2015
Research Centers
Chao Family Comprehensive Cancer Center
Last updated